000 06243cam a2200745Ki 4500
001 9781315269214
003 FlBoTFG
005 20220711212834.0
006 m o d
007 cr cnu---unuuu
008 180921s2018 flu ob 001 0 eng d
040 _aOCoLC-P
_beng
_erda
_epn
_cOCoLC-P
020 _a9781315269214
_q(electronic bk.)
020 _a131526921X
_q(electronic bk.)
020 _a9781351978378
020 _a1351978373
020 _a9781351978354
_q(electronic bk. : Mobipocket)
020 _a1351978357
_q(electronic bk. : Mobipocket)
020 _a9781351978361
_q(electronic bk. : EPUB)
020 _a1351978365
_q(electronic bk. : EPUB)
020 _z9781138035157
020 _z1138035157
035 _a(OCoLC)1053888280
_z(OCoLC)1053868968
035 _a(OCoLC-P)1053888280
050 4 _aRC271.C5
072 7 _aHEA
_x039000
_2bisacsh
072 7 _aMED
_x014000
_2bisacsh
072 7 _aMED
_x022000
_2bisacsh
072 7 _aMED
_x112000
_2bisacsh
072 7 _aMED
_x045000
_2bisacsh
072 7 _aMED
_x071000
_2bisacsh
072 7 _aMED
_x072000
_2bisacsh
072 7 _aTEC
_x027000
_2bisacsh
072 7 _aTDCW
_2bicssc
082 0 4 _a616.99/4061
_223
245 0 0 _aMolecular medicines for cancer :
_bconcepts and applications of nanotechnology /
_c[edited by] Deepak Chitkara, Anupama Mittal and Ram I. Mahato.
264 1 _aBoca Raton :
_bCRC Press,
_c[2018]
300 _a1 online resource (pages)
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aCover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Foreword; Preface; Acknowledgments; Editors; Contributors; Section I : Nanotechnology-Based Approaches to Target Cancer; Chapter 1: Nanomedicines for Cancer; 1.1 Introduction; 1.2 Nanomedicines in Clinical Use and Under Clinical Trials; 1.2.1 Liposome-Based Nanomedicines; 1.2.2 Polymer-Based Nanomedicines; 1.2.3 Protein-Based Nanomedicines; 1.2.4 Micelles-Based Nanomedicines; 1.2.5 Nanotechnology-Based Miscellaneous Nanomedicines; 1.3 Targeting Mechanism of Nanomedicines; 1.3.1 Passive Targeting
505 8 _a1.3.2 Active Targeting1.3.3 Stimuli-Responsive Nanomedicine; 1.4 Design Aspect of Nanomedicines; 1.4.1 Vascular Transport; 1.4.2 Transvascular Transport; 1.4.3 Interstitial Transport; 1.4.4 Intracellular Transport; 1.5 Enhancing Nanomedicine Translation through Clinically Relevant Models; 1.5.1 Standard Xenograft Models with Human Stroma Components; 1.5.2 Patient-Derived Tumor Xenograft (PDX) Model; 1.5.3 Humanized PDX Model; 1.5.4 Human Metastatic Site Model; 1.6 Challenges and Current Limitations; 1.7 Advantages and Disadvantages of Nanotechnology; 1.8 Conclusion; References
505 8 _aChapter 2: Effect of Nanocarrier Size/Surface on Molecular Targeting in Cancer2.1 Introduction; 2.2 Particle Size in Tumor Targeting; 2.2.1 Tumor Type and Pore Cutoff Size; 2.2.2 Circulation in Bloodstream; 2.2.3 Nanoparticle Trafficking and Tumor Internalization; 2.2.4 Cellular Uptake and Cell-Particle Interactions; 2.3 Particle Shape on Tumor Targeting; 2.3.1 Circulation in Bloodstream; 2.3.2 Nanoparticle Transportation and Tumor Internalization; 2.3.3 Cellular Uptake and Cell-Particle Interactions; 2.4 Influence of Nanocarrier Surface Properties on Tumor Targeting
505 8 _a2.4.1 Circulation in Bloodstream2.4.2 Nanoparticle Transportation and Tumor Internalization; 2.4.3 Surface Functionalization with Targeting Tumors; 2.5 Conclusion; References; Chapter 3: Nanocarrier Systems for Anticancer Drug Delivery at the Subcellular Level; 3.1 Introduction; 3.2 Mitochondrial Targeted Drug Delivery; 3.2.1 Mitochondria and Cancer Therapy; 3.2.2 Mitochondrial Drug Delivery; 3.2.2.1 Mitochondriotropic Conjugated Nanocarriers; 3.2.2.2 Mitochondrial-Penetrating Peptide (MPP) Conjugated Nanocarriers; 3.2.2.3 Mitochondrial Targeting Signal (MTS) Conjugated Nanocarriers
505 8 _a3.3 Nuclear Targeted Drug Delivery3.3.1 The Nucleus: Role in Cancer Treatment; 3.3.2 Nuclear Drug Delivery; 3.3.2.1 Nuclear Localization Signal (NLS) Conjugated Nanocarriers; 3.3.2.2 Other Approaches; 3.4 Lysosomal Targeted Drug Delivery; 3.4.1 Lysosomes; 3.4.2 Lysosomal Cell Death; 3.4.3 Lysosomal Drug Delivery; 3.4.3.1 Nanocarriers Containing Lysosomotropic Agents; 3.4.3.2 Nanocarriers Modified with Cathepsin-Specific Substrates; 3.4.3.3 Ceramide Containing Nanocarriers; 3.4.3.4 Metal Nanoparticles; 3.4.3.5 pH-Responsive Nanocarriers; 3.5 Endoplasmic Reticulum (ER) Targeted Drug Delivery
520 _aThe field of molecular medicine covers the medical interventions targeting molecular structures and mechanisms that are involved in disease progression. In cancer, several molecular mechanisms have been shown to impact its progression, aggressiveness and chemoresistance. Increasing evidence demonstrates the role of nanotechnology and outcome of molecular therapy. Several books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. It provides a description of the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology.
588 _aOCLC-licensed vendor bibliographic record.
650 0 _aTumors.
_911942
650 0 _aChemotherapy.
_920073
650 7 _aHEALTH & FITNESS / Diseases / General
_2bisacsh
_98806
650 7 _aMEDICAL / Clinical Medicine
_2bisacsh
_98807
650 7 _aMEDICAL / Diseases
_2bisacsh
_98808
650 7 _aMEDICAL / Evidence-Based Medicine
_2bisacsh
_98809
650 7 _aMEDICAL / Internal Medicine
_2bisacsh
_98810
650 7 _aMEDICAL / Pharmacology
_2bisacsh
_97291
650 7 _aMEDICAL / Pharmacy
_2bisacsh
_920074
650 7 _aTECHNOLOGY / Nanotechnology
_2bisacsh
_912200
700 1 _aChitkara, Deepak,
_eeditor.
_920075
700 1 _aMittal, Anupama,
_eeditor.
_920076
700 1 _aMahato, Ram I.,
_eeditor.
_920077
856 4 0 _3Taylor & Francis
_uhttps://www.taylorfrancis.com/books/9781315269214
856 4 2 _3OCLC metadata license agreement
_uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
942 _cEBK
999 _c72278
_d72278